fluorobenzenes has been researched along with Parkinson Disease in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Boger, HA; Corum, D; Lynn, MK; Schnellmann, RG; Scholpa, NE | 1 |
Bonhaus, DW; McFarland, K; Price, DL | 1 |
Orr, JD | 1 |
1 review(s) available for fluorobenzenes and Parkinson Disease
Article | Year |
---|---|
Statins in the spectrum of neurologic disease.
Topics: Alzheimer Disease; Animals; Atherosclerosis; Cardiovascular Diseases; Diabetic Neuropathies; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Multiple Sclerosis; Nervous System Diseases; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Pyrimidines; Reactive Oxygen Species; Rosuvastatin Calcium; Stroke; Sulfonamides | 2008 |
2 other study(ies) available for fluorobenzenes and Parkinson Disease
Article | Year |
---|---|
5-HT
Topics: Animals; Carbazoles; Corpus Striatum; Fluorobenzenes; Locomotion; Male; Mice; Mitochondria; Organelle Biogenesis; Oxidopamine; Parkinson Disease; Receptor, Serotonin, 5-HT1F; Receptors, Serotonin; Substantia Nigra; Tyrosine 3-Monooxygenase | 2018 |
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System Stimulants; Disease Models, Animal; Dyskinesias; Fenfluramine; Fluorobenzenes; Hyperkinesis; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Psychotic Disorders; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Sensory Gating; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Serotonin Receptor Agonists; Substantia Nigra; Tyrosine 3-Monooxygenase; Urea | 2011 |